Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

@article{GoekoopRuiterman2005ClinicalAR,
  title={Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.},
  author={Yvonne P. M. Goekoop-Ruiterman and Jeska K. de Vries-Bouwstra and Cornelia F. Allaart and Derkjen van Zeben and Pit J.S.M. Kerstens and Johanna M. W. Hazes and Aelko H. Zwinderman and H. Karel Ronday and K. Huub Han and Marie Louise Westedt and Andreas H. Gerards and J H van Groenendael and Willem F. Lems and Michiel V van Krugten and Ferdinand C. Breedveld and Ben A. C. Dijkmans},
  journal={Arthritis and rheumatism},
  year={2005},
  volume={52 11},
  pages={
          3381-90
        }
}
OBJECTIVE Several treatment strategies have proven value in the amelioration of rheumatoid arthritis (RA), but the optimal strategy for preventing long-term joint damage and functional decline is unclear. We undertook this study to compare clinical and radiographic outcomes of 4 different treatment strategies, with intense monitoring in all patients. METHODS In a multicenter, randomized clinical trial, 508 patients were allocated to 1 of 4 treatment strategies: sequential disease-modifying… 
View on PubMed
hapmd.com
1,512 Citations
Highly Influential Citations
24
Background Citations
247
Methods Citations
56
Results Citations
37

Figures and Tables from this paper

1,512 Citations

Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
TLDR
In patients with early, active RA, remarkable clinical improvement and suppression of joint damage progression can be achieved with frequent, objectively steered treatment adjustments.
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
TLDR
Irrespective of initial treatment, an impressive improvement in clinical and radiological outcomes of RA patients can be achieved with dynamic treatment aimed at reducing disease activity, leading to 48% remission, 14% drug-free remission and sustained functional improvement.
Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
TLDR
All 4 DAS-driven treatment strategies resulted in substantial improvements in functional ability, quality of life, and self-assessed VAS scores after 2 years, including significantly faster improvement in all patient-reported measures.
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment
TLDR
This randomized, controlled trial compared 4 treat-to-target strategies for early active RA over 10 years, finding that most patients had persistently reduced disease activity scores, improved functional status, and limited joint damage during follow-up.
Rheumatoid arthritis management of early disease
  • J. Nam
  • Medicine, Biology
    Current opinion in rheumatology
  • 2016
TLDR
In patients with early rheumatoid arthritis, conventional synthetic DMARDs and glucocorticoids used within a treat-to-target setting, and the addition of a bDMARD if required, outcomes have improved significantly.
Comparison of Treatment Strategies in Early Rheumatoid Arthritis
TLDR
All treatment groups achieved similar disease activity after 2 years, although initial monotherapy was often converted to combination therapy during follow-up, and the rapid control produced by initial combination therapy may translate into decreased joint damage.
Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
TLDR
This study confirms that highly effective control of disease activity can be achieved using conventional DMARDs as part of an intensive disease management strategy and within this setting, step-up therapy is at least as effective as parallel triple therapy.
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
TLDR
In patients with recent-onset active RA, drug-free remission was achieved in up to 18% of patients, and DAS-driven treatment maintained clinical and functional improvement, independent of the treatment strategy.
Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy
TLDR
Regardless of induction therapy, patients with continuous low disease activity have similar long-term outcomes, with only a higher proportion of patients in drug-free remission after MTX monotherapy.
BeSt practice: the success of early-targeted treatment in rheumatoid arthritis.
TLDR
Early and maintained targeted treatment has functional and radiological benefits over the first 7 years of the BeSt study and can include drug tapering and (partial, temporary or permanent) discontinuation.
...
...

References

SHOWING 1-10 OF 43 REFERENCES
Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.
TLDR
The results indicate the existence of a therapeutic window in RA within the first 2 years of the disease.
Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone.
TLDR
In patients with early RA, CsA + MTX combination therapy led to a significantly lower rate of 12-month radiographic progression, was effective on inflammatory articular symptoms, and was well tolerated.
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
TLDR
Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
TLDR
An initial 6-month cycle of intensive combination treatment that includes high-dose corticosteroids results in sustained suppression of the rate of radiologic progression in patients with early RA, independent of subsequent antirheumatic therapy.
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Infliximab in active early rheumatoid arthritis
TLDR
Early intervention with infliximab in patients with active RA despite MTX therapy may provide long term benefits by preventing radiographic progression and preserving joint integrity.
Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies.
TLDR
An association between consistent DMARD use and improvement in long-term functional outcomes in RA is supported, which suggest up to a 30 percent reduction in long term disability with consistentDMARD use.
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
TLDR
In patients with rheumatoid arthritis, combination therapy with methotrexate, sulfasalazine, and hydroxychloroquine is more effective than either methot Rexate alone or a combination of sulfas alazine,and hydroxy chloroquine.
...
...